Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2017
|
| gptkbp:ATCCode |
gptkb:L04AC14
|
| gptkbp:brand |
gptkb:Kevzara
|
| gptkbp:contraindication |
active infection
hypersensitivity to sarilumab |
| gptkbp:developedBy |
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals |
| gptkbp:form |
solution for injection
|
| gptkbp:genericName |
gptkb:sarilumab
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kevzara
|
| gptkbp:indication |
rheumatoid arthritis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:monoclonal_antibody
|
| gptkbp:marketedIn |
gptkb:European_Union
gptkb:United_States |
| gptkbp:mechanismOfAction |
IL-6 receptor antagonist
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
injection site reaction
neutropenia upper respiratory tract infection increased liver enzymes |
| gptkbp:target |
gptkb:interleukin-6_receptor
|
| gptkbp:usedIn |
adults
|
| gptkbp:bfsParent |
gptkb:Sanofi
|
| gptkbp:bfsLayer |
5
|